Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02737358 · ClinicalTrials.gov registry record · Phase 2

N-acetylcysteine for Tobacco Use Disorder

A Phase 2 study of Smoking and Nicotine Dependence, sponsored by Medical University of South Carolina.

Completed
Registry status
Phase 2
Development phase
114
Enrollment target
1
Study location

NCT02737358 is a Phase 2 study of Smoking and Nicotine Dependence that has completed, run by Medical University of South Carolina. The registered enrollment target is 114 participants, below the 454-participant average among 123 other Smoking trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02737358, a Phase 2 study of Smoking and Nicotine Dependence, has completed, sponsored by Medical University of South Carolina.

COMPLETED
Registry status
Phase 2
Development phase
114 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to assess the effects of administering N-Acetylcysteine (NAC) to assist in initial cessation and/or relapse prevention in adult cigarette smokers.

Interventions

  • OTHER Placebo
  • DRUG N-acetylcysteine (NAC)

Study Locations (1)

South Carolina

  • Medical University of South Carolina - Charleston

Trial Details

FieldValue
Enrollment Target 114 participants
Start Date 2016-08-30
Est. Completion 2019-10-10
Phase Phase 2

What the Registry Record Tells You About NCT02737358

The ClinicalTrials.gov registry entry for NCT02737358 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 454-participant average among 123 other Smoking trials with a reported enrollment target (75% lower). The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Smoking appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02737358 reports 1 study location spanning 1 distinct geographic area - top geographies include South Carolina.

Frequently Asked Questions

What is clinical trial NCT02737358 about?

NCT02737358 is a clinical study titled "N-acetylcysteine for Tobacco Use Disorder". The purpose of this study is to assess the effects of administering N-Acetylcysteine (NAC) to assist in initial cessation and/or relapse prevention in adult cigarette smokers.

What is the current status of trial NCT02737358?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2016-08-30. Estimated completion is 2019-10-10.

What conditions does trial NCT02737358 study?

This clinical trial studies the following conditions: Smoking, Nicotine Dependence.

What interventions are being tested in trial NCT02737358?

The interventions under investigation include: Placebo (OTHER), N-acetylcysteine (NAC) (DRUG).

Who is sponsoring clinical trial NCT02737358?

This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02737358 being conducted?

This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Smoking

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.